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Improved amputation-free survival in
unreconstructable critical limb ischemia and its
implications for clinical trial design and quality
measurement
Eric Benoit, MD,a Thomas F. O’Donnell Jr, MD,a Georgios D. Kitsios, MD, PhD,b,c and
Mark D. Iafrati, MD,a Boston and Burlington, Mass
Objective: Amputation-free survival (AFS), a composite endpoint of mortality and amputation, is the preferred outcome
measure in critical limb ischemia (CLI). Given the improvements in systemic management of atherosclerosis and
interventional management of limb ischemia over the past 2 decades, we examined whether these outcomes have changed
in patients with CLI without revascularization options (no option-critical limb ischemia [NO-CLI]).
Methods: We reviewed the literature for published 1-year AFS, mortality, and amputation rates from control groups in
NO-CLI trials. Summary proportions of events were estimated by conducting a random effects meta-analysis of
proportions. To determine whether there had been any change in event rates over time, we performed a random effects
meta-regression and a mixed effects logistic regression, both regressed against the variable “final year of recruitment.”
Results: Eleven trials consisting of 886 patients satisfied search criteria, 7 of which presented AFS data. Summary
proportion of events (95% confidence interval) were 0.551 (0.399 to 0.693) for AFS; 0.198 (0.116 to 0.317) for death;
and 0.341 (0.209 to 0.487) for amputation. Regression analyses demonstrated that AFS has risen over time as mortality
rates have fallen, and these improvements are statistically significant. The decrease in amputation rates failed to reach
statistical significance. The lack of published data precluded a quantitative evaluation of any change in the clinical severity
or comorbidities in the NO-CLI population.
Conclusions: AFS and mortality rates in NO-CLI have improved over the past 2 decades. Due to declining event rates,
clinical trials may underestimate treatment effects and thus fail to reach statistical significance unless sample sizes are
increased or unless a subgroup with a higher event rate can be identified. Alternatively, comparing outcomes to historical
values for quality measurement may overestimate treatment effects. Benchmark values of AFS and morality require
periodic review and updating. (J Vasc Surg 2012;55:781-9.)
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eProgress in the management of peripheral arterial dis-
ease (PAD) over the past 2 decades has resulted in a decline
in mortality rates largely due to systemic treatment of
atherosclerotic disease and improved cardiac survival. Nu-
merous population studies have demonstrated a reduction
in the number of major amputations over this same time
period.1-3 Interventional management of PAD has seen a
dramatic increase in the use of endovascular procedures
which has outpaced a modest decrease in open surgical
bypass. These changes have resulted in an overall increase in
the number of revascularizations.4-10
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doi:10.1016/j.jvs.2011.10.089Despite the increase in revascularizations, of the
oughly 500 to 1000 new cases of critical limb ischemia
CLI) per million population per year in industrialized
ountries, an estimated 20% to 40% are not suitable for
rterial reconstruction or have failed revascularization.11-13
his subgroup of patients without revascularization op-
ions (“no option” CLI or NO-CLI) is a particularly chal-
enging population with a high rate of limb loss and death
elated to their large systemic atherosclerotic burden.14 In
he absence of arterial reconstruction options, novel ap-
roaches, such as pharmacologic, gene, or stem cell therapy
re areas of active investigation.
Evaluation of therapy requires measuring its effective-
ess in achieving a given endpoint. There are multiple
utcome measures for CLI. Amputation-free survival
AFS) is a composite metric which incorporates the hard
ndpoints of mortality and amputation, analyzed either as a
ime-to-event (incidence rates) or as binary endpoints (cu-
ulative incidences). AFS is based on the concept that a
uccessful clinical outcome results in a living patient with an
ntact limb. The TransAtlantic Inter-Society Consensus II
TASC II) guidelines state that AFS is the primary outcome
f successful CLI treatment.11 It is one of the principle
ndpoints proposed by the Society for Vascular Surgery
SVS) CLI Working Group and has been used in major
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March 2012782 Benoit et alrandomized controlled trials (RCTs) in CLI such as the
PRoject or Ex-Vivo vein graft ENgineering via Transfec-
tion III (PREVENT III)15 and Bypass versus Angioplasty
in Severe Ischaemia of the Leg (BASIL).16,17 Further-
more, the Food and Drug Administration considers AFS
a preferred primary endpoint for studies of novel CLI
therapies.18
Given the declining mortality and amputation rates and
expansion of revascularization options in patients with
PAD, we questioned whether outcomes in NO-CLI have
changed over time. We sought to determine any change in
AFS, mortality, or amputation in the NO-CLI population
over the past 2 decades by studying the control groups of
patients with CLI in nonrevascularization trials.
While this group of patients with NO-CLI may be
considered a surrogate natural history population, it is
more appropriate to refer to it as a medically managed CLI
population that receives the most current standard of care.
The distinction is important because best medical man-
agement has changed over time with the wide adoption
of statin medications, beta blockade, tighter glucose
control, and improvements in antibiotics. We also eval-
uated whether the NO-CLI population has changed over
time in terms of clinical disease severity and presence of
comorbidities.
METHODS
Systematic review of the literature. To define a med-
ical management population of NO-CLI, we reviewed the
literature for clinical trials of alternate therapies in NO-CLI
and identified patients in the control groups. We queried
the PubMed, Ovid, and Cochrane databases using terms
such as “critical limb ischemia,” “amputation,” “random-
ized controlled trial,” and nonsurgical or nonendovascular
treatments such as “cell therapy,” “spinal cord stimula-
tion,” “gene therapy,” and “prostaglandin therapy.” We
included only clinical trials published in English within the
last 20 years and excluded case series of fewer than five
patients. We examined the references in eligible studies and
review articles to identify additional trials. We excluded
articles which addressed acute limb ischemia, surgical or
endovascular revascularization, ischemia due to diseases
other than atherosclerosis (such as thromboangiitis obliter-
ans), and trials where the CLI portion of the patient pop-
ulation could not be separately evaluated. In an attempt to
minimize heterogeneity, we reviewed the inclusion criteria
of studies to determine that enrolled patients were not
suitable for revascularization for reasons of comorbidity,
anatomy, or previous failed revascularization attempts,
rather than reasons such as patient refusal of an invasive
procedure. We included only patients in the control groups
(ie, those who received best medical management and not
an investigational therapy).
Using these studies, we investigated the endpoints of
AFS, mortality, and amputation at 1 year. To evaluate
changes in disease severity in the NO-CLI population over
time, we reviewed baseline characteristics such as age,
Rutherford class, and comorbidities. tStatistical analysis. We defined the relevant end-
oints as the proportions of patients with the events AFS,
ortality, and amputation at 1 year (cumulative incidence
f events at 1 year). In each study, we estimated the
roportion of each endpoint of interest and estimated
ummary proportions of these endpoints at 1 year across
tudies by conducting a random effects meta-analysis of
roportions with the Freeman-Tukey arcsine transforma-
ion method.19 Between-study heterogeneity was tested
ith Cochran Q (significant if PQ  0.10) and quantified
ith the I2 statistic (an estimate of how much heterogene-
ty is unlikely to be due to chance).
To determine any changes in the published proport-
ons of events over time, we conducted cumulative meta-
nalyses of the proportions, and we examined the plots for
rends over time.20 To formally test for changes in published
roportions of events over time, we performed a random
ffects meta-regression analysis in which we regressed the
roportion of events in each study against the indicator
ariable “final year of recruitment” in each study.21 This
ariable was used as a proxy for the time period during
hich each study was conducted and was considered
ndicative of the standard of care during each time pe-
iod. We examined the coefficient of this indicator vari-
ble for the direction of effect. In a secondary analysis,
e constructed a mixed-effects logistic regression model
or the estimated proportions of events in each study; in
hese models, the effects of the variable “final year of
ecruitment” were considered as fixed, studies varied
dditionally by normally distributed random effects, and
roportion of events were weighted inversely to their
stimated variances according to the binomial distribu-
ion.22 The coefficients of the indicator variable “final
ear of recruitment” were again examined for direction
nd statistical significance. Statistical analyses were con-
ucted using Stata version 11.1/SE (Stata Corp, College
tation, Tex) and Meta-analyst (version 3.0, Tufts
edical Center, Boston, Mass).
ESULTS
No option-critical limb ischemia studies in the
iterature. We identified 11 studies in the literature that
et criteria. All of them provided data on amputation and
ortality at 1 year. Seven provided data on AFS at 1 year
Table I).
One trial was a retrospective review of 5 years of non-
econstructible patients with CLI with 1 year follow-up.23
ne was a prospective study of wound care in patients with
rterial disease from which we included only the patients
hat met CLI criteria.24 The remaining articles were RCTs
f CLI therapy: five spinal cord stimulation studies25-29;
ne pharmacologic trial of a prostaglandin E1 analog
CIRCULASE)30; two gene therapy trials of NV1FGF
TALISMAN31 and TAMARIS32); and one gene therapy
rial of hepatocyte growth factor.33 We included 86 patients
hat met CLI criteria from the wound care study and all the
atients from the control groups of the other 10 trials for a
otal NO-CLI study population of 886 patients.
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Volume 55, Number 3 Benoit et al 783The summary proportions at 1 year (95% confidence
interval [CI]) were as follows: AFS, 0.55 (0.40 to 0.69);
death, 0.20 (0.12 to 0.32); and amputation, 0.34 (0.25 to
0.45). All meta-analyses were characterized by statistically
significant heterogeneity (PQ  0.10).
Change in amputation-free survival, mortality, and
amputation. Inspecting the plots of the cumulative meta-
analyses for each endpoint, we discerned a pattern of de-
clining proportions of events for death and a pattern of
increasing proportions of events for AFS (Fig 1).
We formally tested for change in event rates over time
using both a meta-regression analysis and a mixed-effects
logistic regression, and the results are presented in Table II.
In both analyses for AFS, the coefficients for the variable
“final year of recruitment” were positive and statistically
significant (P  .05), indicating that AFS has increased
over time (Fig 2).
For death and amputation, the meta-regression analy-
ses demonstrated that all coefficients for the variable “final
year of recruitment” were negative, indicating that for each
ascending year of recruitment there has been a reduction in
the published proportion of events (ie, death and amputa-
tion rates have decreased over time). These results were not
statistically significant for amputation but reached border-
line significance for death (P  .056). In the mixed-effects
logistic regression model, the coefficient of the “final year
of recruitment” was statistically significant for death. The
pattern of decreasing proportions of events for death and
amputation provides complementary evidence for the im-
provement in AFS over the same time period.
Because the number of studies that contributed to the
analyses for each endpoint were different (11 studies re-
porting death or amputation and seven studies reporting
AFS), we performed a sensitivity analysis by considering the
seven studies that contributed data to all three endpoints of
interest. The results were similar to the ones obtained in the
main analyses, and we found no changes in statistical sig-
nificance of the coefficient of the indicator variable.
Definition of no option-critical limb ischemia and
inclusion/exclusion criteria. We examined the defini-
Table I. Published 1-year event rates from NO-CLI trials
Author Trial Y
Jivegård Spinal cord stimulation 19
Lepäntalo Retrospective clinical review 19
Claeys Spinal cord stimulation 19
Klomp Spinal cord stimulation 19
Spincemaille Spinal cord stimulation 20
Amann Spinal cord stimulation 20
Marston Wound care only 20
Brass CIRCULASE (PGE1 analog) 20
Nikol TALISMAN (NV1FGF) 20
Hiatt TAMARIS (NV1FGF) 20
Powell Intramuscular hepatocyte GF 20
AFS, Amputation-free survival; Amp, amputation; GF, growth factor; NO-CL
PGE, prostaglandin E; X, not documented.tions of CLI used in each study as well as the inclusion and pxclusion criteria to determine if the enrolled populations
ere similar. The earliest trial simply defined CLI as “severe
hronic (duration more than 2 weeks) lower limb ischemia
n atherosclerotic and diabetic patients with rest pain
nd/or ischemic ulcerations.” They used no hemodynamic
riteria, although the mean ankle-brachial index in the
ontrol group was 0.39  10.06. Later trials defined CLI
ccording to consensus documents which have changed
ver time (eg, the Second European Consensus Document
n Chronic Critical Leg Ischemia from 1992; the original
ASC statement from 2000; and TASC II from 2007).
ith regard to hemodynamic criteria, eight of the 11 trials
sed ankle pressure as an inclusion criteria. Two earlier
rials required values under 50 mm Hg while the five most
ecent trials used 70 mm Hg, although one of these trials
ifferentiated between patients with rest pain (50 mm Hg)
nd tissue loss (70 mm Hg). Six of 11 trials used toe pressures
ess than 30 to 50 mm Hg for inclusion. Four trials used
ranscutaneous oxygen tension of less than 30 mm Hg.
Exclusion criterion were variably delineated with most
rials excluding patients with extensive infection or isch-
mic lesions leading to imminent amputation. Two trials
xplicitly excluded patients with endstage renal disease. No
ther trial reported on the percentage of enrolled patients
n dialysis.
“No option” status was defined by the participating
ascular surgeons and based on anatomy (eg, poor outflow
essels), lack of conduit, extensive comorbidities resulting
n unacceptable risk of a revascularization procedure, as
ell as patients who had previously failed revascularization
ttempts. Of note, one author commented on the fact that
echnical advances over time allowed surgical bypass of
ore distal vessels that would have rendered patients “no
ption” in earlier years of their study.
Change in the no option-critical limb ischemia
opulation. We attempted to analyze change in severity of
isease and prevalence of comorbidities by analyzing base-
ine characteristics of patients in NO-CLI trials. However,
he lack of published data precluded a quantitative analysis.
or example, one trial did not present data on their control
No. Amp Death AFS
26 50.0% 30.8% X
105 46.3% 54.3% 28.0%
41 19.5% 29.3% X
60 48.3% 23.3% 40.0%
18 50.0% 27.8% X
39 46.2% 0.0% 54.0%
86 38.4% 0.0% 61.6%
190 10.5% 10.0% 81.0%
56 33.9% 23.2% 48.2%
259 21.2% 15.1% 66.8%
6 33.3% 16.7% X
option-critical limb ischemia; NV1FGF, nonviral 1 fibroblast growth factor;ear
95
96
96
99
00
03
06
06
08
10
10
I, noatients while another trial did not differentiate the
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March 2012784 Benoit et alFig 1. Cumulative meta-analysis plots for amputation-free survival (AFS) (A), death (B), and amputation (C)
demonstrate decreasing summary proportions of events. Studies are added one at a time according to their “final year
of recruitment” and the results are summarized as each new study is added. Each horizontal line represents the updated
results with summary proportion of events (95% confidence interval [CI] in parentheses) listed to the right. The size of
the squares demonstrates the size of each study.
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Volume 55, Number 3 Benoit et al 785baseline characteristics of patients with CLI from those
with less severe PAD. None of the trials presented the
same set of patient characteristics (eg, none of the trials
before 2003 presented data on hyperlipidemia). Further-
more, the definition of comorbidities varied among tri-
als, which confounds comparison (eg, some trials use
“coronary artery disease” while others use “previous
myocardial infarction”).
Risk factors for amputation and death in the NO-CLI
trials are presented in Table III. The presence of renal
disease was either not reported or used various definitions
and was therefore not included in the table. The mean
patient age ranged from 69 to 75 years with no trend over
time. The percentage of patients with diabetes ranged from
38.3% to 54.44% with no trend over time. With regard to
clinical severity of disease, early studies do not differentiate
between patients with rest pain and tissue loss, whereas
Fig 1.
Table II. Change in AFS, death, and amputation over tim
Endpoint No.
Meta-regression analysis
transformed propo
Coefficient of “final year
of recruitment”
Amputation 11 0.025 (0.062-0.012)
Death 11 0.047 (0.948-0.001)
AFS 7 0.052 (0.001-0.104)
AFS, Amputation-free survival.several of the more recent trials are composed only of batients with tissue loss. We therefore cannot speak to any
rends in the severity of disease in the NO-CLI population.
ISCUSSION
We examined AFS, mortality, and amputation rates in
he NO-CLI population from 1995 to 2010 and found that
ortality rates decreased significantly over time whereas
he corresponding AFS rates have increased. Results were
obust to secondary analyses with different statistical mod-
ls and to sensitivity analyses that excluded specific studies.
e were unable to determine if there has been any change
n disease severity or comorbidities in patients with NO-
LI largely due to lack of consensus in the reporting of
uch factors.
Trends in the treatment of peripheral arterial
isease. Mortality and amputation rates have decreased in
atients with PAD over the past 20 years as demonstrated
tinued
ression analyses for variable “final year of recruitment”
rcsine Mixed-effects logistic regression on
proportions of events
P value
Coefficient of “final year
of recruitment” P value
.157 0.058 (0.124-0.009) .088
.056 0.128 (0.243-0.014) .028
.047 0.109 (0.036-0.183) .004e reg
on a
rtionsy numerous population studies.1,4,6,7,9,10 Over the same
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March 2012786 Benoit et altime, the increase in the number of endovascular proce-
dures has outpaced a decrease in open surgical bypasses,
resulting in an overall increase in the number of patients
receiving revascularization.
Many studies have demonstrated an increase in age and
comorbidities among patients receiving interventions for
CLI. In a study of surgical revascularization for CLI from
1978 to 1997, Conte et al34 demonstrated that, despite
significantly increased severity of CLI, prevalence of co-
morbidities, surgical complexity, patient age, limb salvage,
and survival rates were maintained. Egorova et al6 evaluated
national and state discharge databases for lower extremity
Fig 2. Change in amputation-free survival (AFS) in pa
time. Reference line is derived from meta-regression ana
Table III. Risk factors in NO-CLI trials
Author Year Mean age % Tissue loss % Diabetes
Jivegård 1995 73.0 50.0% 19.2%
Lepäntalo 1996 75.0 NA 50.5%
Claeys 1996 NA NA NA
Klomp 1999 72.1 68.3% 38.3%
Spincemaille 2000 NA NA NA
Amann 2003 NA 33.3% NA
Marston 2006 NA 100.0% NA
Brass 2006 69.7 52.1% 53.7%
Nikol 2008 73.3 100.0% 50.0%
Hiatt 2010 69.0 100.0% 54.0%
Powell 2010 78.0 100.0% 50.0%
NA, Data not available; NO-CLI, no option-critical limb ischemia.revascularizations from 1998 to 2007 and found increased vumbers of revascularization procedures and that, despite
ncreased patient age and comorbidities, the rates of ampu-
ation and mortality declined.
Although improved and expanded access to revascular-
zation has likely contributed to the improved outcomes
een in these older and sicker patients during the last 2
ecades, these improved outcomes are due to more than
ust expanded revascularization. Better diabetes control,
ntiplatelet therapy, infection control, and smoking cessa-
ion may result in improved limb salvage.1 Goodney et al7
ound an increase in podiatric visits and HgbA1c measure-
ents in patients with diabetes as evidence for improved
iabetic management, as well as increased testing for hyper-
ipidemia.
The use of amputation-free survival. There are mul-
iple measures of successful CLI therapy. Surrogate mea-
ures, such as ankle-brachial index or transcutaneous oxy-
en tension, may elucidate mechanisms of therapy, but are
ot necessarily related to clinical outcomes. Functional
utcomes, such as quality of life, are valuable but may be
nfluenced by factors other than disease state or therapy.
FS captures two hard endpoints, mortality and amputa-
ion, that are obviously important to patients and clinicians.
he TASC II guidelines suggest that AFS is a primary
easure of success in CLI treatment11 and AFS has become
he accepted endpoint for multiple RCTs in CLI.15,17
Recently the SVS-CLI Working Group published ob-
ective performance goals (OPGs), benchmark values for
with no option-critical limb ischemia (NO-CLI) over
Size of circles demonstrates weighting of each study.tientsarious endpoints.35 One of the strengths of the OPGs was
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Volume 55, Number 3 Benoit et al 787to define a standardized set of outcome measurements,
with major adverse limb event and postoperative death
determining early safety and AFS capturing later clinical
efficacy. Results were derived from patients undergoing
open bypass from several RCTs. Values at 1 year were AFS
76.5%, mortality 14.3%, and amputation 11.1%. The intent
of the OPGs was to establish benchmark values against
which novel endovascular therapies could be measured,
thereby providing an evaluation method less burdensome
than RCTs. But benchmark values can also become a
powerful tool for quality comparison and improvement, as
recently demonstrated by Goodney et al.36 They interro-
gated their regional vascular registry to evaluate outcomes
of over 1000 patients undergoing lower extremity bypass
and found that their results were not statistically different
from the OPGs (AFS 84.4%, mortality 8.4%, and amputa-
tion 9.1%). The OPGs are likely to gain further use in the
evaluation of novel therapies and as quality control bench-
marks for current therapy.
AFS from our NO-CLI population cannot be directly
compared to the OPG AFS because the latter were derived
from revascularized patients. Our finding that AFS has
increased over time, however, suggests an overall improve-
ment in the level of medical care for patients with CLI and
supports the statement by the SVS-CLI Working Group
that the OPGs require reassessment and updating.
Some authors have questioned whether limb salvage
and AFS are the most appropriate endpoints in patients
with CLI given their poor prognosis.14,37 One of the
criticisms of AFS is the inclusion of all-cause mortality in
the endpoint; this may obscure the impact of a therapy
directed at limb salvage. However, if AFS in NO-CLI is
rising over time and this change is due to decreasing
mortality, the “noise” introduced by the mortality compo-
nent may lessen, improving the use of AFS as a measure of
efficacy. Our demonstration of improving AFS in NO-CLI
raises a further point: if outcomes are improving without
revascularization, any planned intervention must demon-
strate an even greater improvement in efficacy while main-
taining a safety profile that limits morbidity and mortality.
Impact of declining event rates on clinical trials and
quality measurement. The medically managed NO-CLI
population serves as the control group for RCTs of novel
treatments such as gene or stem cell therapies. Yet a declin-
ing event rate in this group (as evidenced by increasing
AFS) makes it more difficult to demonstrate a difference in
outcome between experimental therapy and control. This
has been seen in other cardiovascular diseases such as
stroke38 and coronary disease.39
Kent and Trikalinos39 highlighted the impact of declin-
ing control event rates on clinical trial design. As baseline
outcomes improve, demonstrating the smaller marginal
efficacy of a novel therapeutic becomes increasingly diffi-
cult. Studies must become exponentially larger, with asso-
ciated increases in costs and complexity, or run the risk of
being underpowered. Kent and Trikalinos39 offer several
solutions to this problem, including “idiopathic control tate inflation,” that is, identifying a clinically relevant sub-
opulation with an increased event rate.
In NO-CLI, we previously demonstrated that patients
ith tissue loss (Rutherford 5) have a much higher ampu-
ation rate than those with rest pain (Rutherford 4).40 A
ixed population of patients with CLI will have a diluted
vent rate, at least with regard to amputation possibly
esulting in a baseline event rate too small to allow for
etection of a treatment effect as defined by AFS.
In this report, we found that many of the more recent
tudies were comprised only of patients with tissue loss.
his population can be expected to have a higher event rate
han a mixed population, yet these studies demonstrated
ower AFS than earlier trials which contained both patients
ith R4 and R5. This suggests that increasing AFS may be
ven more pronounced in the overall NO-CLI population.
Because AFS is rising over time, the use of historical
enchmarks (such as OPGs) for comparison of novel ther-
py may exaggerate the impact of new therapies. This
verestimation of treatment effect also holds true for
omparing clinical performance against OPGs for quality
easurement.
Rising AFS means that RCTs risk underestimating
reatment effects and thus may fail to reach statistical sig-
ificance unless sample sizes are increased or unless a sub-
opulation of patients with a higher event rate is identified.
e found that in order to maintain the same statistical
ower for AFS, using data in this report from the time
eriod of the earliest study to the most recent one would
equire nearly a threefold increase in sample size.
In the planning of clinical trials of CLI, estimation of
ontrol event rates warrants careful attention. Due to fall-
ng event rates, it becomes increasingly important to iden-
ify the appropriate patient population and to use the most
ppropriate endpoint for that group. The right question
ust be asked of the right patients to give a trial the best
hance of succeeding.
We suggest that although AFS is an important outcome
easure, due to the declining death rate in all patients with
LI, as well as the low mortality and amputation rates
ithin rest pain patients (R4), AFS is not an ideal endpoint
or a mixed population of patients with CLI. However, AFS
s an appropriate primary endpoint for trials restricted to
atients with tissue loss (R5). Studies that contain a mixed
LI population require different endpoints, and at a min-
mum require stratified randomization to distribute disease
everity evenly between treatment groups. The rising AFS
ust be taken into account when estimating treatment
ffect and sample size calculation.
Limitations of current study. Our study is a meta-
nalysis and is only as good as the methods of the compo-
ent articles. One of the major confounding factors in this
tudy is the lack of data on clinical classification by the
utherford criteria, specifically tissue loss in many of the
arly studies. The contribution of tissue loss to increased
mputation rates and mortality has only recently been
emonstrated.35,41,42 It is interesting to note that two of
he more recent NO-CLI trials treated only patients with
11
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ity rates than early trials with mixed populations. Analysis of
other major risk factors, such as end-stage renal disease, was
hampered by variability in definitions and reporting.
Lacking individual patient data, it is impossible for us to
determine how the severity of disease in the NO-CLI
population has changed over time. Advances in surgical
technique, anesthesia, and endovascular procedures have
expanded revascularization options to a greater number of
patients with CLI. Has this culled the healthier patients
from the NO-CLI population? On the other hand, have
more stringent adverse event reporting requirements re-
sulted in RCTs enrolling patients with less severe disease?
Our analysis was unable to answer these questions.
We have relied on the proxy “final year of recruitment”
to facilitate our analysis. We wanted to test temporal trends
and in order to evaluate change over time we had to assign
each trial a given time point, therefore, we used “final year
of recruitment” to approximate the time of conduct of each
study. Certainly trials are conducted over a variable length
of time, not a single year, and changes may occur within a
trial, but the “final year of recruitment” was an approxima-
tion made to allow our analysis.
CONCLUSIONS
Using a population of patients with NO-CLI derived
from control groups of clinical trials, we have demonstrated
that AFS has risen over the past 2 decades. This is due to a
decrease in mortality rates. This increase in AFS has impli-
cations for evaluation of CLI therapy. Clinical trials may
underestimate treatment effects and thus fail to reach sta-
tistical significance unless sample sizes are increased or
unless a subgroup of patients with a higher event rate can be
identified. If AFS is used as a primary endpoint in CLI, we
suggest that the study population should consist of patients
with tissue loss so as to maintain a sufficient event rate to
demonstrate treatment effect. Comparing outcomes to his-
torical values for quality measurement may overestimate
treatment effects. Benchmark values of AFS and mortality
in NO-CLI require periodic review and updating.
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